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Abstract
Recently, deep generative models have revealed itself as a promising way of performing de novo molecule
design. However, previous research has focused mainly on generating SMILES strings instead of molecular
graphs. Although current graph generative models are available, they are often too general and computationally
expensive, which restricts their application to molecules with small sizes. In this work, a new de novo molecular
design framework is proposed based on a type sequential graph generators that do not use atom level recurrent
units. Compared with previous graph generative models, the proposed method is much more tuned for
molecule generation and have been scaled up to cover significantly larger molecules in the ChEMBL database.
It is shown that the graph-based model outperforms SMILES based models in a variety of metrics, especially in
the rate of valid outputs. For the application of drug design tasks, conditional graph generative model is
employed. This method offers higher flexibility compared to previous fine-tuning based approach and is suitable
for generation based on multiple objectives. This approach is applied to solve several drug design problems,
including the generation of compounds containing a given scaffold, generation of compounds with specific
drug-likeness and synthetic accessibility requirements, as well as generating dual inhibitors against JNK3 and
GSK3β. Results show high enrichment rates for outputs satisfying the given requirements.
Keywords: Deep Learning; De Novo Drug Design; Graph Generative Model
Introduction
The ultimate goal of drug design is the discovery of
new chemical entities with desirable pharmacologi-
cal properties. Achieving this goal requires medicinal
chemists to perform searching and optimization in-
side the space of new molecules. This task is proved
to be extremely difficult, mainly due to the size and
complexity of the search space. It is estimated that
there are around 1060 ∼ 10100 synthetically avail-
able molecules[1]. Meanwhile, the space of chemical
compounds exhibits a discontinues structure, making
searching difficult to perform[2].
De novo molecular design aims at assisting this
processes with computer-based methods. Early works
have developed various algorithms to produce new
molecular structures, such as atom based elonga-
tion or fragment based combination[3, 4]. Those al-
gorithms are often coupled with global optimization
techniques such as ant colony optimization[5, 6], ge-
Full list of author information is available at the end of the article
netic algorithms[7, 8] or particle swam optimization[9]
for the generation of molecules with desired properties.
Recent developments in deep learning[10] have shed
new light on the area of de novo molecule genera-
tion. Works have shown that deep generative mod-
els are very effective at modeling the SMILES rep-
resentation of molecules using recurrent neural net-
works (RNN), an architecture that has been exten-
sively applied to tasks related sequential data[11].
Segler et al[12] applied SMILES language model (LM)
to the task of generating focused molecule libraries
by fine-tuning the trained network with a smaller
set of molecules with desirable properties. Olivecrona
et al[13] used a GRU[14] based LM trained on the
ChEMBL[15] dataset to generate SMILES string. The
mode is then fine-tuned using reinforcement learning
for the generation of molecules with specific require-
ments. Popova et al[16] propose to integrate the gen-
erative and predictive network together in the gener-
ation phase. Segler et al[12] applied SMILES LM to
the task of generating focused molecule libraries by
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fine-tuning the trained network with a smaller set of
molecules with desirable properties. Beside language
model, Go´mez-Bombarelli et al[13] used variational au-
toencoder (VAE)[17] to generate drug-like compounds
from ZINC database[18]. This work aims at obtain-
ing a bi-directional mapping between molecule space
and a continuous latent space so that operations on
molecules can be achieved by manipulating the latent
representation. Blaschke et al[19] compared different
architectures for VAE and applied it to the task of
designing active compounds against DRD2.
The works described above demonstrated the effec-
tiveness of SMILES based model regarding molecule
generation. However, producing valid SMILES strings
requires the model to learn rules that are irrelevant
to molecular structures, such as the SMILES gram-
mar and atom ordering, which adds unnecessary bur-
den to the training process, making the SMILES string
a less preferable representation compared to molecu-
lar graphs. Research in deep learning has recently en-
abled the direct generation of molecular graphs. John-
son et al[20] proposed a sequential generation approach
for graphs. Though their implementation is mainly for
reasoning tasks, this framework provided is potentially
applicable to molecule generation. Compared with this
approach, a more recent method[21] was proposed for
generating the entire graph all at once. This model has
been successfully applied to the generation of small
molecular graphs. The implementation that is most
similar to ours is by the recent work by Li et al[22]
using a sequential decoding scheme similar to that by
Johnson et al. Decoding invariance is introduced by
sampling different atom ordering from a predefined dis-
tribution. This method has been applied to the gener-
ation of molecules with less than 20 heavy atoms from
ChEMBL dataset. Though inspiring, the methods dis-
cussed above have a few common problems. First of all,
the generators proposed are relatively general. This de-
sign allows those techniques to be applied to various
scenarios but requires further optimization for appli-
cation in molecule generation. Secondly, many of those
models suffer from scalability issue, which restricts the
application to molecules with small sizes.
In this work, we propose a graph-based generator
that is more suited for molecules. The model is scaled
to cover compounds containing up to 50 heavy atoms
in the ChEMBL dataset. Results show the graph-based
model proposed is able to outperform SMILES based
methods in a variety metrics, including the rate of valid
outputs, KL and JS divergence of molecular properties,
as well as NLL loss. A conditional version of the model
is employed to solve various drug design related tasks
with multiple objectives, and promising performance
has been demonstrated according to the results.
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Figure 1 Cimetidine and its graph based representation In
the graph based generative models, molecules are represented
as graphs G = (V,E), where atoms are bonds are viewed as
nodes and edges respectively (see a and b). Atom types are
specified by three parameters: the atomic symbol (or equally
the atomic number), the number of explicit hydrogens
attached, and the number of formal charges (see c). For bond
types, only single, double, triple and aromatic bonds are
considered in this work (see d).
Methods
Molecular Graph
Molecular graph is a way of representating the struc-
tural information of molecules using graph objects
(G = (V,E)), where atoms and bonds as viewed as
graph nodes (v ∈ V ) and edges (e ∈ E). Each node
v in V is labeled with its corresponding atom type.
In this work, the atom type is specified using three
variables: the atomic symbol (or equally the atomic
number), the number of explicit hydrogens attached,
and the number of formal charges. For example, the ni-
trogen atom in pyrrole can be represented as the triple
(“N”, 1, 0). Similarly, the edges in E are labeled with
bond types. Only four types of bonds are considered
in this work: single, double, triple and aromatic.
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Figure 2 A schematic representation of molecule generation process Starting with the empty graph G0, initialization is performed
to add the first atom. At each step, a graph transition (append, connect or terminate) is sampled and performed on the intermediate
molecule structure. The probability for sampling each transition is given by pθ(t|Gi, ..., G0), which is parametrized using deep neural
network. Finally, termination operation is performed to end the generation.
The set of all atom types and all bond types are
denoted as A and B respectively. A is extracted from
molecules in the ChEMBL dataset (see Supplementary
Text 1), and contains 33 elements in total. A visualized
demonstration of molecular graph is given in Figure 1.
Graph Generative Model
We now consider the deep generative models that can
directly output molecular graphs. In this work, we
mainly focus on sequential graph generators, which
builds graph by iteratively refining its intermediate
structure. The process starts from the empty graph
G0 = (∅, ∅). At step i, a graph transition ti is selected
from the set of all available transition actions T (Gi)
based on the generation history (G0, ..., Gi). The se-
lection is done by sampling ti from a probability dis-
tribution ti ∼ pθ(ti|Gi, ..., G0) parametrized by neural
network. Then, ti is performed on Gi to get the graph
structure for the next step Gi+1 = ti(Gi). At the final
step n, termination operation t∗ is performed and the
model outputs G = Gn as the final product.
The entire process is illustrated in Figure 2. We
call the mapping T , which determines all available
graph transitions at each step, a decoding scheme.
The sequence r = ((G0, t0), (G1, t1), ..., (Gn, tn)) is
called a decoding route of G, and the distribution
pθ(ti|Gi, ..., G0) is called a decoding policy.
Previous graph generative models are usually too
general and less optimized for the generation of molec-
ular graphs. Here we offer the following optimizations:
1 A much simpler decoding scheme T is used to de-
crease the number of steps required for generation.
2 No atom level recurrent unit is used in the de-
coding policy. Instead, we explored two other op-
tions: (1) parametrizing the decoding policy as a
Markov process and (2) using only molecule level
recurrent unit. Those modifications helps to in-
crease the scalability of the model.
3 During the calculation of log-likelihood loss,
we sample r from a parametrized distribution
qα(r|G). The parameter α controls the degree of
randomness of qα, offering higher flexibility for
the model.
The following three sections are devoted to the de-
tailed discussions of the optimizations above.
Decoding Scheme
The transitions in T (Gi) given the intermediate state
Gi is restricted to the following four types:
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Figure 3 The two type of graph generative architectures explored in this work a. MolMP: This architecture models graph
generation as a Markov process, where the transition of Gi only depends on the current state of the graph, not on the history. b.
MolRNN: This architecture adds a single molecule level recurrent unit to MolMP.
1 Initialization: At the beginning of the genera-
tion, the only allowed transition is to add the first
atom to the empty graph G0.
2 Append: This action adds a new atom to Gi and
connect it to an existing atom with a new bond.
3 Connect: This action connects two existing
atoms v1, v2 ∈ Vi with a new bond. For simplicity,
we only allow connections to start from the latest
appended atom v∗, which means that v1 = v∗.
4 Termination: End the generation process. This
action is denoted as t∗.
The entire process is shown in Figure 2, and a
more detailed illustration is provided in Figure S1 and
S2(Additional file 2). In theory, T (G) should not con-
tain actions that violate the validity constraints of
molecules. However, in order to test the ability for the
model to learn those constraints, we do not explicity
exclude those actions from T (G) during training.
Note that compared with the implementation in [22],
the action of adding new atom and the action of con-
necting it to the molecule is merged into a single “ap-
pend” step. This helps to reduce the number of steps
during generation. It is easy to show that the num-
ber of steps required for generating graph G = (V,E)
equals exactly to |E| + 2, which is generally much
smaller than the length of the corresponding SMILES
string (as shown in Figure S3(Additional file 2)).
Decoding Policy
During generation, the decoding policy pθ need to
specify the probability value for each graph transition
in T (Gi). More specifically, pθ need to output the fol-
lowing probability values:
1 pAv for each v ∈ Vi: A matrix with size |A| × |B|,
whose element (pv)ab represents the probability
of appending a new atom of type a ∈ A to atom
v with a new bond of type b ∈ B.
2 pCv for each v ∈ Vi: A vector with size |B|, whose
element (pCv )b represents the probability of con-
necting the latest added atom v∗ with v using a
new bond of type b ∈ B.
3 p∗: A scalar value indicating the probability of
terminating the generation.
A visualized depiction of pAv , p
C
v and p
∗ is shown
in Figure 2. The decoding policy pθ is parameterized
using neural network. At each step, the network ac-
cepts the the decoding history (G0, ..., Gi) as input and
calculates the probability values (pAv , p
C
v , p
∗) as out-
put. In this work, we explored two novel graph gen-
eration architectures, namely MolMP and MolRNN.
Unlike the methods proposed in [20, 22], the two ar-
chitectures do not involve atom level recurrency, which
helps to increase the scalability of the model.
MolMP
The first architecture models graph generation as a
Markov process, where the transition of Gi only de-
pends on the current state of the graph, not on the
history (Figure 3a). This means that pθ(t|Gi, ..., G0) =
pθ(t|Gi). We refer to this method as MolMP. Since this
type of architecture does not include any recurrent
units, it will be less expensive compared with RNN
based models. Moreover, the computation at different
steps can be easily parallelized during training. The
detailed architecture of MolMP is given as follows:
1 An initial atom embedding h0v is first generated
for each atom v:
h0v = Embeddingθ(v) (1)
h0v is determined based on the following informa-
tion: (1) the atom type of v and (2) whether v is
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the latest appended atom. The dimension of h0v is
set to 16.
2 h0v is passed to a sequence of L graph convolu-
tional layers:
hlv = GraphConv
l
θ(h
l−1
v , Gi) (2)
Where l = 1, ..., L. The outputs from all graph
convolutional layers are then concatenated to-
gether, followed by batch normalization and
ReLU:
hskipv = relu(bn(Concat(h
1
v, ...,h
L
v ))) (3)
Except the first layer, each convolutional layer
GraphConvlθ adopts a “BN-ReLU-Conv” struc-
ture as suggested in [23]. The detailed architecture
of graph convolution is described in “Graph Con-
volution”. We use six convolution layers in this
work (L = 6), each with 32, 64, 128, 128, 256, 256
output units.
3 hskipv is passed to the fully connected network
MLPFCθ to obtain the final atom level represen-
tation hv.
hv = MLP
FC
θ (h
skip
v ) (4)
MLPFCθ consists of two linear layers, with 256 and
512 output units each. Batch normalization and
ReLU are applied after each layer.
4 Average pooling is applied to obtain the molecule
level representation hGi :
hGi = AvgPool([hv]v∈Vi) (5)
5 The activation value for each transition in T (Gi)
is obtained using hv and hGi .
sv = MLPθ(hv,hGi) (6)
s∗ = MLP∗θ(hGi) (7)
For each atom v ∈ Vi, sv is a matrix of size
|A| × |B| + |B|, which is subsequently split into
sAv and s
C
v with size |A| × |B| and |B|respectively.
s∗ is a scalar containing the activation value for
termination action t∗. MLPθis a two layer fully
connected network with hidden size 128. MLP∗ is
a one layer fully connected network. Both MLPθ
and MLP∗ uses exponential activiaton in the out-
put layer.
Embedding (16)
GraphConv1
Conv (32)
GraphConv2
BatchNorm
ReLU
Conv (64)
GraphConv3
BatchNorm
ReLU
Conv (128)
GraphConv4
BatchNorm
ReLU
Conv (128)
GraphConv5
BatchNorm
ReLU
Conv (256)
GraphConv6
BatchNorm
ReLU
Conv (256)
Concat
BatchNorm
ReLU
MLPFC
Linear (128)
BatchNorm
ReLU
Linear (512)
BatchNorm
ReLU
AvgPool
𝐡� 𝐡�
MLP
Linear (128)
BatchNorm
ReLU
Linear
(|𝐴|�|𝛣|+|𝛣|)
Exp
MLP*
Linear (1)
Exp
𝐬�A 𝐬�C 𝑠*
Softmax
𝐩�A 𝐩�B 𝑝*
Input
Figure 4 Network architecture for MolMP This figure shows
the detailed model architecture for MolMP. MolRNN adopts a
structure highly similar to that of MolMP, except the inclusion
of the molecule level recurrent unit.
6 The activation values are normalized to give the
probability values:
pAv = s
A
v /S (8)
pCv = s
C
v /S (9)
p∗ = s∗/S (10)
where S =
∑
vab(s
A
v )ab +
∑
vb(s
C
v )b + s
∗
The architecture of the entire network is shown in
Figure 4.
Li et al. Page 6 of 22
Input
(1) BN
(2) ReLU
𝐡�
Output
(1) Concat
(2) Linear
𝐡�⁺¹
Graph convolution
(1) Input representation
b=”SINGLE”
+
b=”AROMATIC”
+
d=2
d=3
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Figure 5 Architecture of graph convolutional layer At each layer, the output representation for atom i is given by: (1) the input
representation of i from previous layers, (2) information of local neighbors and (3) information of distant neighbors.
MolRNN
The second architecture adds a single molecule level
recurrent unit to MolMP, as shown in Figure 3. We
refer to this method as MolRNN. The model architec-
ture is specified as follows:
1 First of all, the model generates the atom level
(hv, v ∈ Vi) and molecule level (hGi) representa-
tion for the graph state Gi. This part of the net-
work uses the same architecture as that in MolMP.
2 Given hv and hGi , the hidden state of the
molecule level recurrent unit (hRNNi ) is updated
as:
hRNNi+1 = RNNθ(h
RNN
i ,hv∗,hGi) (11)
Where hv∗ is the representation of the latest ap-
pended atom v∗. The recurrent network RNNθ is
employed using three GRU layers with a hidden
size of 512.
3 The probability values pAv , p
C
v , p
∗ are calculated
in the same manner as MolMP by replacing hGi
in eq. 6 and eq. 7 with hRNNi+1 .
The overall architecture of MolRNN is highly sim-
ilar to that of MolMP. However, it is found that the
molecule level recurrent unit in MolRNN provides sig-
nificant improvements to the model performance (see
“Model Performance and Sample Quality”), while in-
ducing little extra computational cost compared with
MolMP.
Graph Convolution
In this work, we rely on graph convolutional network
(GCN)[24] to extract information from graph states
Gi. Each graph convolutional layer adopts the “BN-
ReLU-Conv” structure as described before. In terms
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of the convolution part, the architecture is structured
as follows:
hlv =W
lhl−1v +∑
b∈B
Θlb
∑
u∈Nbondb (v)
hl−1u +
∑
1<d≤D
Φld
∑
u∈Npathd (v)
hl−1u
(12)
Where hlv is output representation of atom v at layer
l, and hl−1v is the input representation. N
bond
b (v) is
the set of all atoms directly connected to atom v with
bond of type b, and Npathd (v) is the set of all atoms
whose distance to atom v equals to d. D represents
the receptive field size, which is set to 3 in this work.
W l, Θlb and Φ
l
d are weight parameters of layer l.
Briefly speaking, at each layer l, the output repre-
sentation of atom v (hlv) is calculated according to the
following information:
1 The input representation of v (hl−1v ),
2 Information of local neighbors, which is given by∑
b∈B Θ
l
b
∑
u∈Nbondb (v) h
l−1
u . Note that this part of
information is conditioned on the bond type b be-
tween v and its neighborhood atom u.
3 Information of remote neighbors, given by∑
1<d≤D Φ
l
d
∑
u∈Npathd (v) h
l−1
u . This part of infor-
mation is conditioned on the distance d between
v and its remote neighbor u.
The architecture is illustrated in Figure 5. Our im-
plementation of graph convolution is similar to the
edge conditioned convolution by Simonovsky el al[25],
except that we also include the information of remote
neighbors of v in order to reach larger receptive field
with fewer layers.
Likelihood Function
To train the generative model, we need to maximize
the log-likelihood pθ(G) for the training samples. How-
ever, for the step-wise generative models discussed
above, the likelihood is only tractable for a given de-
coding route r = ((G0, t0), (G1, t1), ..., (Gn, tn)):
log pθ(G, r) =
n∑
i=0
log pθ(ti|Gi, ..., G0) (13)
While the marginal likelihood can be computed as:
log pθ(G) = log
∑
r∈R(G)
pθ(G, r) (14)
Where R(G) is the set of all possible decoding route
for G. The marginal likelihood function is intractable
for most molecules encountered in drug design. One
way to resolve this problem is to use importance sam-
pling as proposed in [22]:
log pθ(G) = logEr∼q(r|G)[
pθ(G, r)
q(r|G) ] (15)
Where q(r|G) is a predefined distribution on R(G).
Both the deterministic and the fully randomized
q(r|G) were explored in the previous work[22]. How-
ever, a more desirable solution would lie in somewhere
between deterministic decoding and fully randomized
decoding. In this work, instead of sample from the
distribution q(r|G), we sample r from distribution
qα(r|G) that is parameterized by 0 ≤ α ≤ 1. qα(r|G)
is designed such that the decoding will largely follow
depth first decoding with canonical ordering, but at
each step, there is a small possibility 1 − α that the
model will make a random mistake. In this way, the
parameter α measures can be used to control the ran-
domness of the distribution qα. The algorithm is shown
in Supplementary Text 4(Additional file 1).
log pθ(G) = logEr∼qα(r|G)[
pθ(G, r)
qα(r|G) ]
≥ log 1
k
k∑
i=1
pθ(G, ri)
qα(ri|G)
(16)
For α = 1, the distribution falls back to the deter-
ministic decoding. The parameter α is treated as a
hyperparameter which is optimized for model perfor-
mance. We tried α ∈ {1.0, 0.8, 0.6} on both MolMP
and MolRNN.
Conditional Generative Model
Most molecule design tasks require to produce com-
pounds satisfying certain criteria, such as being syn-
thetically available or having a high affinity for a cer-
tain target. Currently, the most popular solution is to
fine-tune the existing model so that it can be suited
for a specific task[12, 13, 16]. However, modeling mul-
tiple objectives is challenging for this type of mod-
els. Herein, conditional generative model is propose for
generation tasks with specific requirements. We first
convert the given requirement to the numerial rep-
resentation called conditional code (c), and the gen-
erative model is then modified to be conditioned on
c. For graph generative model, this means that the
decoding policy is now pθ(ti|Gi, ..., G0, c) (see Figure
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6). Compared with fine-tuning based methods, condi-
tional model can be easily applied to multi-objective
and multi-task settings.
Both graph based and SMILES based conditional
generators are implemented in this work. For graph
based model, the graph convolution is modified to in-
clude c as input:
hlv =W
lhl−1v +∑
b∈B
Θlb
∑
u∈Nbondb (v)
hl−1u +
∑
1<d≤D
Φld
∑
u∈Npathd (v)
hl−1u + Ψ
lc
(17)
Simply state, c is included in the graph convolu-
dion architecture by adding an additional term Ψlc
to the unconditional implementation in eq. 12. For
SMILELS based model, the conditional code is in-
cluded by concatenating it with the input at each step:
x′i = Concat(xi, c). Where xi is the one-hot represen-
tation of the SMILES charactor input at step i.
Conditional models have already been used by the
previous work[21] for molecule generation, but was re-
stricted to small molecules and have only used sim-
ple properties such as the number of heavy atoms as
conditional codes. Here, the model is applied to tasks
that are much more related to drug design, including
scaffold-based generation, property-based generation
and the design of dual inhibitor of JNK3 and GSK-
3β (see 6).
Scaffold-Based Generation
The concept of molecular scaffold has long been
of significant importance in medicinal chemistry[26].
Though various definitions are available, the most
widely accepted definition is given by Bemis and
Murcko[27], who proposed derive the scaffold of a given
molecule by removing all side chain atoms. Studies
have found various scaffolds that have privileged char-
acteristics in terms of the activity of certain target[28–
30]. Once such privileged structure is found, a related
task is to produce compound libraries containing such
scaffolds for subsequent screening.
Here, conditional graph generative model is applied
to generate compounds containing scaffold s, which is
drawnfrom the pre-defined scaffold set S = {si}NSi=1.
The set S is extracted from the list of approved
drugs in DrugBank[31]. Two types of structures are
extracted from the molecules to construct S: (1) the
Bemis-Murcko scaffolds, and (2) ring assemblies. Ring
assemblies are included in S since we found that in-
cluding extra structural information beside Bemis-
Murcko scaffolds helps to improve the conditional
Query
Conditonal
code (𝐜)
Results
Scaffold
N
NN
N
N
N
Scaffold
fingerprint
N
N
N
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b
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c
Molecules satisfying
the requirement
d
Bioactivity
fingerprint
Dual inhibitors against
GSK-3β and JNK3
N
H
N N
N
Highly drug-like
GSK-3β active
HN
O
Cl
HN
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a
Figure 6 Conditonal generative models a. For the generation
of molecules based on requriements, the requriement(query) is
first converted to the numerical representation called
conditoinal code c, the generative model is then modified to
be conditioned on c. b. Scaffold based molecule generation. c.
Generation based on drug-likeness and synthetic accessibility.
d. Designing of dual inhibitors of JNK3 and GSK-3β
generation performance. Detailed scaffold extraction
workflow is shown in Supplementary Text 2 (Addi-
tional file 1). For each molecule G, the conditional code
c = (c1, c2, ..., cNS ) is set to be the binary vector such
that ci = 1 if G contains si as substructure, and ci = 0
otherwise. We refer c as the scaffold fingerprint of G,
since it can in fact be viewed as a substructure fin-
gerprint based on scaffold set S. To generate molecule
containing substructure s ∈ S, the fingerprint cs for s
is used as conditional code. The output should contain
two type of molecules:
1 Molecules containing s as its Bemis-Murcko scaf-
fold.
2 Molecules whose Bemis-Murcko scaffold contains
s but does not reside inside S.
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Figure 7 Workflow for scaffold based molecule generation. Scaffold set S is first extracted from compounds in DrugBank. The
conditional code c is set to be the substructure fingerprint based on S. Training is performed with the training samples labeled with
cG. After training, scaffold based generation is performed using the fingerprint cs of the query scaffold s ∈ S.
The procedure is better demonstrated in Figure 7.
Using this method, a detailed control can be performed
on the scaffold of the output structure.
Generation Based on Synthetic Accessibility and
Drug-likeness
Drug-likeness and synthetic accessibility are two prop-
erties that have significant importance in the devel-
opment of novo drug candidate. Drug-likeness mea-
sures the consistency of a given compound with the
currently known drugs in terms of the structural or
physical properties and is frequently used to filter out
obvious non-drug like compounds in the early phase
of screening[32, 33]. Synthetic accessibility is also an
important property for de novo drug design since sub-
sequent experimental validation requires synthesis of
the given compound[34]. In this task, the model is re-
quired to generate molecules according to a given level
of drug-likeness and synthetic accessibility. The drug-
likeness is measured using the Quantitative Estimate
of Drug-likeness (QED)[35], and synthetic accessibility
is evaluated using the SA score[34]. The conditional
code c is defined as c = (QED,SA), where the QED
and SA score is all calculated using RDKit[36].
In practice, instead of specifying a single value of
QED and SA score, we often use intervals to express
the requirements for desired output molecules. This
means that we are required to sample molecules from
the distribution pθ(G|c ∈ C) = Ec∼p(c|c∈C)[pθ(G|c)],
where the generation requirement is described as a set
C instead of a single point c. The sampling involves
a two-step process by first drawing c from p(c|c ∈
C), and then drawing G from pθ(G|c). Sampling from
p(c|c ∈ C) can be achieved by first sample c from
p(c) using molecules from the test set, then filter c
according to the requirement c ∈ C.
Designing Dual Inhibitor Against JNK3 and GSK-3β
With the ability to model multiple requirements at
once, conditional generative models can be used to de-
sign compounds with specific activity profiles for mul-
tiple targets. Here, we consider the task of designing
dual inhibitors against both c-Jun N-terminal kinase
3 (JNK3) and glycogen synthase kinase-3 beta (GSK-
3β). Both of the two targets are serine/threonine (S/T)
kinases, and have shown to be related to the pathogen-
esis of various types of diseases[37, 38]. Notably, both
JNK3 and GSK-3β are shown to be potential target
in the treatment of Alzheimer’s disease (AD). Jointly
inhibiting JNK3 and GSK-3β may provide potential
benefit for the treatment of AD.
The conditional code is set to be c = (cJNK3, cGSK−3β),
where cJNK3, cGSK−3β are binary values indicating
whether the compound is active against JNK3 and
GSK-3β. For compounds in the ChEMBL dataset,
cJNK3 and cGSK−3β are labeled using a separately
trained predictor. Random forest (RF) classifier, which
has been demonstrated to provide good performance
for kinase activity prediction[39], is used as the pre-
dictor for GSK-3β and JNK3 activity, with ECFP6
(extended connectivity fingerprint[40] with a diam-
eter of 6) as the descriptor. The predictive model
Li et al. Page 10 of 22
is trained using activity data from ExCAPE-DB[41],
which is an integrated database with activity values
from ChEMBL and PubChem[42]. Workflow for data
extraction and predictor training is provided in Sup-
plementary Text 3. It is found that there is only 1.2%
of molecules in ChEMBL that is predicted to be ac-
tive against JNK3 or GSK-3β. This imbalance results
in low enrichment rate during conditioned generation.
For better result, the model is first trained under the
unconditioned setting, and then fine-tuned based on
the 1.2% molecules mentioned above.
Training Details
The graph generative models are trained using the
ChEMBL dataset. The data processing workflow
largely follows Olivecrona et al [13], as described in
Supplementary Text 1. MXNet[43] is used to imple-
ment the networks, and Adam optimizer[44] is used
for network training. An initial learning rate of 0.001
is used together with a decay rate of 0.001 for every
100 iterations. Other parameters of the optimizer are
set to be the default values suggested in [44] (that is,
β1 = 0.9, β2 = 0.999 and  = 10
−8). The training lasts
for 5 epochs, and the size of each mini-batch is set to
200 during the training.
During training, the decoding route is drawn from
the distribution qα(r|G). We tried three α values: 1.0,
0.8 and 0.6, as discussed previously. For α = 1.0, k is
set to 1 and the training can be performed on a single
Nvidia GeForce GTX 1080Ti GPU for both MolMP
and MolRNN. The training lasts for 14h for MolMP
and 16h for MolRNN. For α = 0.8 and α = 0.6, k is
set to 5 and the training is performed synchronously
on 4 GPUs. The training lasts for 30h for MolMP and
35h for MolRNN.
For scaffold based and property based generation
tasks, the conditonal graph generator is trained using
the same setting as unconditional model. For the gen-
eration of GSK-3β and JNK3 inhibitors, the model is
first trained using the full dataset, and the fine tuned
on the subset that is predicted to be active against
GSK-3β or JNK3. The fine-tuning uses a learning rate
of 0.0001 and a decay rate of 0.002 for every 100 iter-
ations. The fine-tuning lasts for 10 epochs, and takes
1h to finish.
In theory, the hyperparameters for the models men-
tioned above, including the training condition (batch
size, learning rate, decay rate, β1, β2), model architec-
tures(the number of convolutional layers, the hidden
size in each layer) as well as α, should be optimized
to achieve the best performance. However, due to the
computational cost of both MolMP and MolRNN, we
are unable to systematically optimize the hyperparam-
eters. A througout discussion is only given for α, which
determines the degree of randomness of qα. No opti-
mization is performed on model architecture except
fitting it into the memory.
SMILES Based Methods
The proposed graph-based model is compared with
several SMILES based models for model performance
and sample quality. Two type of methods, variational
autoencoder (VAE) and language model (LM), are
considered in this comparison. The implementation
of SMILES VAE follows Go´mez-Bombarelli et al[2].
The encoder contains three 1D convolutional layers,
with 9, 9, 10 filters and 9, 9, 11 kernels each, and
a fully connected layer with 435 hidden units. The
model uses 196 latent variables and a decoder with
three GRU layers with 488 hidden units. VAE for se-
quential data faces from the issue of “optimization
challenge”[45, 46]. While the original implementation
uses KL-annealing to tackle this problem, we follow
the method provided by Kingma et al[47] by control-
ling the level of free bits. This offers higher flexibility
and stability compared with KL-annealing. We restrict
the minimal level of free bits to 0.03 for each latent
variable.
For LM, two types recurrent units are adopted. The
first type uses GRU, and includes two architectures:
the first architecture (SMILES GRU1) consists of three
GRU layers with 512 hidden units each, and the sec-
ond (SMILES GRU2), uses a wider GRU architec-
ture with 1024 units, following the implementation by
Olivecrona et al[13]. Beside GRU, we also included a
LSTM based SMILES language model following Segler
et al[12]. This architecture uses three LSTM layers,
each with 1024 units.
Evaluation Metrics
Several metrics have been employed to evaluate the
performance of generative models:
Sample Validity
To test whether the generative models are capable of
producing chemically correct outputs, 300,000 struc-
tures are generated for each model, and subsequently
evalulated by RDKit for the rate of valid outputs. We
also evaluate the ability of each model to produce novel
structures. This is done by accessing the rate of gener-
ated compounds that do not occure inside the training
set.
DKL and DJS for Molecular Properties
A good molecule generator should correctly model the
distribution of important molecular properties. There-
fore, the distribution of molecular weight (MW), log-
partition coefficient (LogP) and QED between the gen-
erated dataset (pg) and the test set (pdata) is compared
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for each method, using Kullback–Leibler divergence
(DKL):
DKL(pg||pdata) =
∫
R
pg(x) log
pg(x)
pdata(x)
dx (18)
and Jensen–Shannon divergence(DJS):
DJS(pg||pdata) =1
2
DKL(pg||pg + pdata
2
)+
1
2
DKL(pdata||pg + pdata
2
)
(19)
DKL and DJS are widely used in deep generated mod-
els for both training [17, 48] and evaluation [49]. Here,
the two values are determined using kernel density
method implemented in SciPy [50]. We used a gaus-
sian kernel with bandwidth selected based on Scott’s
Rule[51].
Negative Log-Likelihood
The model performance is also evaluated using the
negative log-likelihood (NLL) on the test set {Gi}Ni=1.
To offer comparison between graph and SMILES based
generative model, NLL is evaluated using the canoni-
cal ordering as follows:
NLL = − 1
N
N∑
i=1
log pθ(Gi, r
∗
i ) (20)
Note that for graph based models, NLL is only re-
ported for models trained on α = 1. For models using
α < 1, the value caluclated above can not be directly
compared between different models. Therefore, we rely
more on other metrics such as DKL and DJS . Also,
for SMILES VAE, importance sampling is performed
to obtain a tighter bound. The number of samples is
set to be 100 (k = 100).
Performance Metrics for Conditional Generative
Models
For discrete conditional codes c, let Mc be the set con-
taining molecules sampled from distribution pθ(G|c).
Mc is obtained by first sampling molecule graphs con-
ditioned on c and then removing invalid molecules.
The size of |Mc| is set to 1,000. Let Ncc′ be the set of
molecules in Mc that satisfy the condition c
′ (c′ may
be different from c). The ratio Kcc′ is defined as:
Kcc′ =
|Ncc′ |
|Mc| (21)
The matrix Kcc′ can be used to evaluate the ability
of the model to control the output based on condi-
tional code c. When c = c′, this value gives the rate
of correctly generated outputs, denoted by Rc. High
quality conditional models should have a high value
of Rc and low values of Kcc′ for c 6= c′. In paractice,
we find that the value of Kcc′ for scaffold and prop-
erty based generation is significantly samller than Rc
and have relatively low influence on the model’s per-
formance. Therefore, the result of Kcc′ is omitted for
scaffold and property based task, and is only reported
for the task of kinase inhibitor design.
Let R0c be the rate of molecules in the training data
that satisfy condition c. The enrichment over random
EORc is defined as:
EORc =
Rc
R0c
(22)
The definition is similar to that used in previous
work[12], except that in their implementation R0c is
calculated using the generated samples from the un-
conditioned model pθ(G). For continuous codes, a sub-
set C of the conditional code space is used to de-
scribe the generation requirements. MC is sampled
from pθ(G|c ∈ C), and values for KCC′ , RC and
EORC can be calculated in a similar manner.
For target based generation task, the rate of re-
produced molecules is also reported following previ-
ous works[12, 13]. Take JNK3 as an example. Dur-
ing the evaluation, two sets of outputs are gener-
ated using two conditions: JNK3(+), GSK-3β (-) and
JNK3(+), GSK-3β(+). The two set of outputs are de-
noted Mc1and Mc2respectively. Here, the size of |Mc1 |
and |Mc2 | are both set to 50,000. Let T be the set
containing the active molecules within the test set of
JNK3. The rate of reproduced molecules (reprod) is
calculated as:
reprod =
|(Mc1 ∪Mc2) ∩ T |
|T | (23)
For GSK-3β, the calculation can be done in a similar
manner.
Finally, we access the diversity of the generated out-
puts by conditional models using the internal diversity
I proposed in [52]:
I(M) =
1
|M |2
∑
(x,y)∈M×M
Td(x, y) (24)
Where M is the set of sampled molecules, and
Td(x, y) is the Tanimoto-distance between the two
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molecules x and y. Td(x, y) is defined using the
Tanimoto-similarity Ts: Td(x, y) = 1− Ts(x, y).
Results and Discussion
Model Performance and Sample Quality
Several randomly generated samples from MolRNN
are grouped by molecular weight and shown in Figure
8. The comparison between SMILES based and graph
based models (MolMP and MolRNN) have been per-
formed, and the results is summarized in Table 1 and
Table 2. We first analysed the model performance in
terms of NLL. According to the result, MolRNN is able
to achieve the best performance with NLL = 24.08.
As for MolMP, although it is unable to outperform
SMILES GRU2 and SMILES LSTM, it achieves bet-
ter performance compared with SMILES GRU1 and
SMILES VAE. It should be noted that SMILES GRU1
contains 4 × 106 parameters, while MolMP only con-
tains 1× 106. This indicates that graph based models
are more efficient in parameter usage. It should also
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Figure 8 Output samples by MolRNN The outputs are
grouped by molecular weight(MW): a. MW<300; b.
300≤MW<500; c. MW≥500
be noted that the NLL values used in this comparison
are only relatively loose bonds as it is evaluated us-
ing only deterministic decoding route. Therefore, we
focuces more on other evaluation metrics that are dis-
cussed below.
In terms of the rate of valid outputs and the rate
of valid and novel outputs, both MolRNN and MolMP
outperform all SMILES based methods. It is also noted
that changing α from 1.0 to 0.8 can significantly
increase the rate of valid outputs for both MolMP
and MolRNN. Further decreasing α can produce only
margincal effect. The high validity in output structures
of graph-based model is not surprising as the genera-
tion of SMILES poses much stricter rules to the output
compared with the generation of molecular graphs.
Figure 9a and Figure 9b summarize respectively the
common mistakes made by SMILES-based and graph-
based model during generation. Results in Figure 9a
show that the most common cause of invalid output
for SMILES based models is grammar mistakes, such
as unclosed parentheses or unpaired ring numberings.
But for the graph-based model, the majority of invalid
output is caused by broken aromaticity, as demon-
strated in Figure 9c. This is likely a result of stepwise
decoding pattern of graph-based models, as the de-
coder can only see part of the aromatic structure dur-
Breaks the 4N+2 rule 
for aromaticity
None ring atom marked 
aromatic
Explict valence greater 
than permited 
Others
60%25%
13%
2%
Breaks the 4N+2 rule
for aromaticity
None ring atom  marked aromatic
H
N N
Unclosed parentheses
Unclosed rings
Breaks the 4N+2 rule 
for aromaticity
Others
45%
40%
14%
1%
a
b
c
Figure 9 Common mistakes made by: a. SMILES based
model and b graph based model. c Examples of broken
aromaticity occurred during graph generation.
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Table 1 Comparison between SMILES based and graph-based generators in NLL and output validity. Results are reported as
Mean± StdDev. The model giving the best performance in each metric is highlighted in boldface
Model NLL % valid % novel % valid & novel
SMILES VAE 30.39± 0.25 0.804± 0.016 0.986± 0.000 0.793± 0.016
SMILES GRU1 27.57± 0.03 0.886± 0.002 0.984± 0.000 0.872± 0.002
SMILES GRU2 24.45± 0.02 0.932± 0.002 0.965± 0.001 0.899± 0.002
SMILES LSTM 25.43± 0.04 0.935± 0.006 0.975± 0.001 0.912± 0.006
MolMP (α = 1.0) 26.25± 0.02 0.952± 0.002 0.98± 0.001 0.933± 0.001
MolMP (α = 0.8) - 0.962± 0.002 0.984± 0.001 0.946± 0.001
MolMP (α = 0.6) - 0.963± 0.001 0.988± 0.001 0.951± 0.001
MolRNN (α = 1.0) 24.08± 0.03 0.967± 0.001 0.959± 0.000 0.928± 0.001
MolRNN (α = 0.8) - 0.970± 0.001 0.976± 0.001 0.947± 0.001
MolRNN (α = 0.6) - 0.970± 0.001 0.985± 0.000 0.955± 0.001
Table 2 Comparison between SMILES based and graph-based generators in DKL(×10−3) and DJS(×10−3). Results are reported as
Mean± StdDev. The model giving the best performance in each metric is highlighted in boldface
MW LogP QED
Model DKL DJS DKL DJS DKL DJS
SMILES VAE 13.5± 0.6 3.6± 0.2 3.9± 0.4 0.9± 0.1 2.6± 0.4 0.6± 0.1
SMILES GRU1 8.6± 0.4 2.3± 0.1 3.1± 0.3 0.7± 0.0 1.5± 0.3 0.3± 0.1
SMILES GRU2 7.8± 0.3 2.0± 0.1 1.4± 0.2 0.3± 0.0 2.2± 0.3 0.5± 0.1
SMILES LSTM 6.5± 0.7 1.8± 0.2 3.4± 1.2 0.8± 0.3 1.9± 1.3 0.4± 0.3
MolMP (α = 1.0) 11.5± 1.3 3.4± 0.4 7.0± 1.8 1.7± 0.4 5.3± 1.2 1.3± 0.3
MolMP (α = 0.8) 8.3± 1.6 2.4± 0.5 4.3± 1.2 0.9± 0.2 2.7± 0.8 0.6± 0.2
MolMP (α = 0.6) 8.4± 1.0 2.4± 0.3 5.0± 1.3 1.1± 0.4 3.0± 0.9 0.7± 0.2
MolRNN (α = 1.0) 5.0± 0.6 1.4± 0.2 2.8± 0.5 0.7± 0.1 2.0± 0.6 0.5± 0.1
MolRNN (α = 0.8) 4.1± 0.7 1.1± 0.2 1.6± 0.3 0.3± 0.1 1.0± 0.2 0.2± 0.0
MolRNN (α = 0.6) 3.3± 0.2 0.9± 0.1 3.0± 0.4 0.5± 0.1 1.1± 0.4 0.2± 0.1
ing generation, while the determination of aromatic-
ity requires the information of the entire ring. It is
also observed that mistakes related to atom valance
are relatively minor, meaning that those rules are easy
to learning using graph convolution.
Graph-based methods also have the advantage of giv-
ing the highly interpretable outputs compared with
SMILES. This means that a large portion of invalid
outputs can be easily corrected if necessary. For exam-
ple, broken aromaticity can be restored by literately
refining the number explicit hydrogens of aromatic
atoms, and unclosed aromatic rings can be corrected
simply by connecting the two ends using a new aro-
matic bond. Though possible, those corrections may
introduce additional bias to the output samples de-
pending on the implementation, thus not adopted in
the subsequent evaluations.
Next, we investigate the ability for the generators
to learn the distribution of molecular properties, as
demonstrated in Table 2. Results have shown that
MolRNN gives the best performance in DKL and
DJS for molecular weight (MW) and QED, while
SMILES GRU2 gives the best performance for LogP.
For MolMP, although it is able to outperform SMILES
GRU1 in NLL, it fails to give better performance
in DKL and DJS . This observation suggest that the
molecule level recurrent unit in MolRNN can signifi-
cantly imporved the ability for the model to learn in-
formation about the data distribution.
When it comes to the influence of α to DKL and
DJS , it is found that changing α from 1.0 to 0.8 can
significantly improve the perforamnce of MolMP and
MolRNN for all molecular properties. Further decreas-
ing α to 0.6 will have different effect for MolMP and
MolRNN. For MolMP, this will hurt the overall perfor-
mance of DKL and DJS , while for MolRNN, this will
inprove the performance for molecular weight, but will
significantly decrease the performance of LogP. Over-
all, α = 0.8 will be a better choise for MolMP, and
α = 0.6 will be more suited for MolRNN.
Generally, MolRNN have showed significant advan-
tages among all generative mdoels considered. In the
subsequent evaluation of conditonal generative models,
the best performing graph based model (MolRNN) and
the best performing SMILES based model (SMILES
GRU2) are implemented as conditonal models and are
compared among all tasks.
Scaffold-Based Generation
In the first task, conditional generative models are
trained to produce molecules based on a given scaf-
fold. To illustrate the result, scaffold 1, extracted from
the antihypertensive drug Candesartan , is used as an
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Figure 10 Results of scaffold based molecule generation using scaffold 1-4 as conditions
example, along with several related scaffolds (scaffold
2-4) derived from scaffold 1 (Figure 10). Conditional
codes c are constructed for each type of scaffold, and
output structures are produced according to the cor-
responding code.
Results for both the SMILES based and graph based
conditional generator are given in Table 3. In terms of
output validity, graph based model is able to produce a
higher fraction of valid outputs for scaffolds 1-4, com-
pared with SMILES based methods. This is similar to
the results of unconditional models
In terms of the rate of correctly generated outputs
(Rc), although the models are unable to achieve 100%
correctness, the Rc results are significantly higher than
R0c, offering high enrichment rate over random. Both
graph based and SMILES based model are able to
achieve EORc > 1, 000 for scaffold 1-3 as well as
EORc > 100 for scaffold 4, showing promising ability
for the model to produce enriched output according to
the given scaffold query. By comparing the result of
Rc between the two type of architectures, it is found
that graph based model have a higher performance for
scaffold 3, while SMILES based method have a higher
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Table 3 Performance of graph based and SMILES based model on scaffold diversification tasks. Results are reported as
Mean± StdDev. The model giving the best performance in each metric is highlighted in boldface
Condition (c) R0 Model % valid Rc EORc Diversity
scaffold 1 7.9× 10−5 Graph 0.931± 0.008 0.86± 0.03 10865 0.496± 0.015
SMILES 0.924± 0.005 0.87± 0.01 10976 0.498± 0.015
scaffold 2 1.1× 10−4 Graph 0.900± 0.016 0.77± 0.04 6972 0.531± 0.02
SMILES 0.896± 0.011 0.84± 0.01 7607 0.495± 0.015
scaffold 3 7.9× 10−5 Graph 0.940± 0.019 0.56± 0.08 7086 0.683± 0.023
SMILES 0.898± 0.024 0.37± 0.07 4623 0.704± 0.022
scaffold 4 5.8× 10−3 Graph 0.982± 0.001 0.88± 0.01 151 0.815± 0.001
SMILES 0.969± 0.002 0.88± 0.00 151 0.823± 0.00
performance for scaffold 2. The two model have similar
performance for scaffold 1 and scaffold 4.
The structural diversity of the output samples is also
evaluated for each model. It is found that SMILES
based model tends to produce outputs that are more
diverse compared with graph based model, except for
scaffold 3. This may indicate that the graph based
model tends to be slightly overtrained compared with
SMILES based model. However, those differences are
relatively minor compared with the standard deviation
of each value.
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Figure 11 Location of C1 ∼ C4 and c1 ∼ c4: a.
Distribution of QED and SAscore in the ChEMBL dataset; b.
Location of the conditional codes c1 , c2, c3 and c4 and
conditional sets C1, C2, C3 and C4 used in the evaluation.
Several generated samples by graph based model are
given for each scaffold in Figure 10. Recall that the
outputs given scaffold s should contain two type of
molecules: (1) molecules with s as its Bemis-Murcko
scaffold and (2) molecule whose Bemis-Murcko scaf-
fold contains s but does not reside inside S. Both types
are observed for scaffold 1-4 as shown in Figure 10.
By further investigating the generated samples, it is
observed that the model seems to have learnt about
the side chains characteristics each scaffold. For ex-
ample, samples generated from scaffold 1-3 usually
have their substitutions occur at restricted positions,
and frequently contains a long aliphatic side chain. In-
terestingly, this actually reflects the structural activ-
ity relationship (SAR) for angiotensin II (Ang II) re-
ceptor antagonists[53]. In fact, scaffold 1-3 have long
been treated as a privileged structure against Ang II
receptors[26], and as a result, molecules with scaffold
1-3 are largely biased to those who matches the SAR
rules for the target. When trained with the biased
dataset, the model can memorize the underlying struc-
tural activity relationship as a byproduct of scaffold
based learning. This characteristic is beneficial for the
generation of libraries containing specified privileged
structures.
Generation Based on Drug-likeness and Synthetic
Accessibility
In this task, the generative model is used to pro-
duce molecules according to the requirement on drug-
likeness and synthetic accessibility. The conditional
code is specified as c = (QED,SA). In the first exper-
iments, the models are required to generate molecules
based on the following requirements expressed as sub-
sets of conditional code space: C1 = (0.84, 1)×(0, 1.9),
C2 = (0, 0.27)×(0, 2.5), C3 = (0.84, 1)×(3.4,+∞) and
C4 = (0, 0.27)× (4.8,+∞).
The values are determined from the distribution of
QED and SA in ChEMBL dataset (see Figure 11a)
using the 90% and 10% quantile. The conditions are
illustrated in Figure 11d. The four sets represent four
classes of molecules respectively and the first class C1,
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Table 4 Performance of graph based and SMILES based model on property based generation tasks. Results are reported as
Mean± StdDev. The model giving the best performance in each metric is highlighted in boldface
Condition (C) R0 Model % valid RC EORC Diversity
C1 0.009
Graph 0.997± 0.000 0.55± 0.01 61 0.814± 0.002
SMILES 0.995± 0.001 0.51± 0.00 57 0.827± 0.000
C2 0.012
Graph 0.970± 0.002 0.55± 0.01 46 0.848± 0.001
SMILES 0.944± 0.001 0.52± 0.00 43 0.849± 0.001
C3 0.011
Graph 0.957± 0.001 0.35± 0.01 32 0.872± 0.001
SMILES 0.894± 0.007 0.31± 0.00 28 0.878± 0.00
C4 0.008
Graph 0.929± 0.003 0.73± 0.01 91 0.865± 0.000
SMILES 0.613± 0.015 0.66± 0.00 82 0.867± 0.00
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Figure 12 Distribution of QED and SAscore for generated results: a-d: Distribution of QED and SAscore of molecules generated
under conditions C1, C2 , C3 , C4 respectively. The conditions C1 ∼ C4 are shown as intervals represented by error bar. e-h:
Distribution of QED and SAscore of molecules generated using single point conditions, which are c1, c2, c3 and c4 respectively. The
conditions c1 ∼ c4 are represented as dots in the plot.
which contains structures with high drug-likeness and
high synthetic accessibility, defines the set of com-
pounds that are most important for drug design.
Quantitative evaluation of graph based and SMILES
based models are demonstrated in Table 4. Again, un-
der all conditions(C1 ∼ C4), the graph based model
is able to outperform SMILES based model on the
rate of valid outputs. The difference is most signif-
icant for conditions requiring high SAscore (that is,
C3 and C4). This observation suggests that SMILES
based model have difficulty in generating complexed
structures while maintaining the structural validity.
The graph based model also provides better perfor-
mance in terms of RC and EORC as shown in Ta-
ble 4. It is noted that both graph and SMILES based
models have relatively bad performance on condition
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Figure 13 Samples generated under the four predefined conditions on drug-likeness and synthetic accessibility score
C3, which corresponds to molecules with high drug-
likeness and low synthetic accessibility. However, this
result is easy to understand. Since the definition of
drug-likeness contains the requriement for high syn-
thetic accessibility, finding molecules with high QED
score and high SAscore is in itself a difficult task. For
other conditions, the RC results for both models varies
from 50% to 70%. The values are lower compared
with scaffold based task, but nonetheless showing en-
richments for all conditions over the distribution from
ChEMBL. The diversity of generated samples are also
reported. Similar to the observation in “Scaffold-Based
Generation”, SMILES based method is able to pro-
duce outputs with slighly higher diversity compared
with graph based method.
For a visualized demonstration, the distributions of
QED and SA score for the output samples from graph
based generator are shown in Figure 12a-d. Random
samples are also chosen for each class and are visual-
ization in Figure 13. The structural features for the
output samples are mostly consistent with the prede-
fined conditions, with small and simple molecules for
C1 and highly complexed molecules for C4.
Note that conditional model also supports genera-
tion based on a given point of QED and SAscore.
This possibility is demonstrated for visualization us-
ing graph based conditional model. The molecule gen-
eration is now conditioned on single points of condi-
tional code c. Here, we use four different conditions as
specified as follows: c1 = (0.84, 1.9), c2 = (0.27, 2.5),
c3 = (0.84, 3.8) and c4 = (0.27, 4.8).
The distributions of QED and SA for the output
molecules by graph based model are shown in Figure
11e-h. Results show that although the requirement is
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Test Set (GSK-3β)
Generated: GSK-3β(+), JNK3(-)
Test Set (GSK-3β)
Generated: GSK-3β(+), JNK3(+)
Test Set (JNK3)
Generated: GSK-3β(-), JNK3(+)
Test Set (JNK3)
Generated: GSK-3β(+), JNK3(+)
Figure 14 Visualizing the distribution of generated samples for each target. The figure shows the t-SNE visualization of: a.
molecules form test set of GSK-3β and samples conditioned on JNK3(-), GSK-3β(+) b. molecules from test set of GSK-3β and
samples conditioned on JNK3(+), GSK-3β(+). c. molecules from test set of JNK3 and samples conditioned on JNK3(+),
GSK-3β(-) d. molecules from test set of JNK3 and samples conditioned on JNK3(+), GSK-3β(+)
specified using a single value of QED and SA score, the
distribution of the two properties for output samples
are relatively dispersed. This result is not surprising
since the QED and SA score are relatively abstract
descriptions of structural features of molecules, and a
small modification of molecule structure may lead to
significant changes in QED and SA scores. Nonethe-
less, it can be found that the generated samples are
enriched around the corresponding code c. It is also ob-
served that the distribution of SA is more concentrated
than that of QED. This is probably because that SA
is direct measurement of molecular graph complexity,
which may be easier to model for the graph based gen-
erator. In contrast, QED is a more abstract descriptor
related to various molecular properties.
Generating Dual Inhibitors for JNK3 and GSK-3β
In this task, the model is used to generate dual in-
hibitor for JNK3 and GSK-3β. A predictive model is
first used to label the conditional code for ChEMBL
dataset, and the conditional graph generator is trained
on the labeled training set. The two predictors yield
good results in general, with AUC=0.983 for JNK3
and AUC=0.984 for GSK-3β. The ROC curves for the
two models are show in Figure S4(Additional file 2).
Results for both the SMILES based and graph based
conditional generator are given in Table 5. In terms
of output validity, graph based model outperforms
SMILES based model in generating GSK-3β selective
and JNK3 selective compounds, but for the genera-
tion of dual inhibitors, SMILES based model outper-
forms graph based model. In terms of Rc and EORc,
SMILES based model achieves better performance in
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Table 5 Performance of graph based and SMILES based model on inhibitor generation, Results are reported as Mean± StdDev. The
model giving the best performance in each metric is highlighted in boldface
Condition (c) R0 Model % valid Rc EORc Diversity
GSK-3β(+)
JNK3β(+)
0.0008
Graph 0.939± 0.007 0.53± 0.01 666 0.824± 0.003
SMILES 0.959± 0.003 0.56± 0.01 697 0.820± 0.002
GSK-3β(+)
JNK3β(-)
0.01
Graph 0.932± 0.007 0.42± 0.01 42 0.866± 0.001
SMILES 0.928± 0.003 0.47± 0.01 47 0.862± 0.001
GSK-3β(-)
JNK3β(+)
0.0008
Graph 0.955± 0.003 0.61± 0.00 759 0.834± 0.001
SMILES 0.944± 0.003 0.56± 0.01 698 0.837± 0.001
Table 6 The Kcc′ matrix for kinase inhibitor generation task, the diagnal elements Kcc = Rc are omitted since they have been reported
in Table 5. Results are reported as Mean± StdDev. The model giving the best performance in each metric is highlighted in boldface
Results(c′)
Condition(c) Model
GSK-3β(+),
JNK3β(+)
GSK-3β(+),
JNK3β(-)
GSK-3β(-),
JNK3β(+)
GSK-3β(+),
JNK3β(+)
Graph - 0.178± 0.007 0.018± 0.001
SMILES - 0.167± 0.010 0.063± 0.006
GSK-3β(+),
JNK3β(-)
Graph 0.034± 0.001 - 0.003± 0.000
SMILES 0.082± 0.007 - 0.023± 0.002
GSK-3β(-),
JNK3β(+)
Graph 0.024± 0.004 0.022± 0.002 -
SMILES 0.083± 0.007 0.057± 0.002 -
the task of generating dual inhibitors and the task
of generating selective inhibitors for GSK-3β, while
graph based model achieves better performance in the
task of generating JNK3 selective inhibitors.The Kcc′
matrices for graph based and SMILES based model are
shown in Table 6. For both graph based and SMILES
based model, it is noted that when generating com-
pounds that is active to both JNK3 and GSK-3β,
there is a significant amount of outputs falling into
the category of GSK-3β positive and JNK3 negative.
Nonetheless, in terms of the enrichment over random
EORc, the two models are able to achieve high per-
formance for all selectivity combinations. Note that se-
lective inhibitors for GSK-3β are relatively enriched in
ChEMBL database, according to the result of the pre-
dictor. In comparison, the selective inhibitors against
JNK3 and the dual inhibitor for both JNK3 and GSK-
3β are much rarer. However, the model is still able
to achieve significant enrichment for the two types of
selectivity. The result shows potential application for
target combinations that have low data enrichment
rate.
To better demonstrate the structural distribution
of the generated samples, visualization based on t-
SNE[54]is performed using the ECFP6 fingerprint. The
generated samples under different selectivity specifi-
cations and molecules in the test set for each target
are projected into two-dimensional embeddings and
are shown in Figure 14a-d. The result illustrates the
structural distribution is well-matched between gener-
ated molecules and the test set. It is also shown that
the conditional generator tends to produce molecules
near the test set samples, which is consistent with ob-
servations based on other methods[12]. It is also ob-
served that molecules generated under different se-
lectivity condition occupy distinct region of chemical
space.
For each selectivity condition, several molecules are
sampled using the model and are demonstrated in Fig-
ure 15a-c. By investigating the generated structures
in detail, it can be observed that the model tends
to generate samples containing well-established scaf-
fold for the corresponding target. For JNK3, struc-
tures such as diaminopurines[55] and triazolones[56],
which has frequently been used in the design of JNK
inhibitors, show high occurrence in the generated sam-
ples. This observation is the same for GSK-3β, with
example like 2,3-bis-arylmaleimides, a class of widely
studied inhibitor of GSK-3[57]. On the other hand,
aminopyrimidines are frequently shown in the outputs
of all selectivity conditions, but they are more enriched
in generated dual inhibitors. Those observations show
good interpretability of the outputs, and indicate that
the structural features of generated samples are in line
with the existing knowledge about the two targets.
Finally, we report the percentage of reproduced sam-
ples from the test set for each target. From the result,
10.3% of molecules are reproduced for JNK3 and, 6.0%
of molecules are reproduced for GSK-3β. Note that
molecules in the test sets for each targets have been
excluded from the ChEMBL training set in this task,
which means that the method is capable of generat-
ing molecules that have been confirmed to be positive,
without seeing them in the training set of predictive
model and conditional generative model.
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Figure 15 Samples conditioned on different selectivity conditions. a-c. Generated samples under different condition of selectivity,
a for Dual inhibitors, b for GSK-3β selective inhibitors, and c for JNK3 selective inhibitors. d-e. Several recovered actives of
JNK3(see d) and GSK-3β (see e)
Several recovered actives are shown in Figure 15d-
e. Those molecules show relatively high diversity in
structure, indicating that the model does not collapse
to a subgroup of active compounds. A quantitative
evaluation is performed using the internal diversity,
and the result shows that the recovered GSK-3β in-
hibitors have a internal diversity of 0.819, while the
recovered JNK3 inhibitors have a internal diversity of
0.761. Those values are relatively close to the diversity
of test set molecules, which are 0.867 for GSK-3β and
0.852 for JNK3.
Conclusion
In this work, a new framework for de novo molecular
design is proposed based on graph generative model
and is applied to solve different drug design problems.
The graph generator is designed to be more fitted to
the tasks of molecule generation by using a simple de-
coding scheme and a graph convolutional architecture
that is less computationally expensive. Furthermore,
a more flexible way of introducing decoding invari-
ance is also suggested. The method is trained using
molecules in ChEMBL dataset and has been demon-
strated to have better performance compared with
SMILES based methods, especially in terms of the rate
of valid outputs.
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To generate molecules with specific requirements, we
propose to use conditional generative model, which
provides higher flexibility and is much easier to train
compared with previous fine-tuning based methods.
The model is applied to solve problems that is highly
related to drug design, such as generating molecules
based on a given scaffold, generating molecules with
good drug-likeness and synthetic accessibility and the
generation of molecules with specific profile against
multiple targets. The high enrichment rates presented
in the results show that the conditional generative
model provides a promising solution for many real-life
drug design tasks.
This work can be extended in various aspects. First
of all, the models used in this work completely ig-
nores the stereochemistry information for molecules.
In fact, stereochemistry is extremely important in the
process of drug development, and introducing this in-
formation helps to improve the applicability of ex-
isting models. Secondly, for the target based genera-
tion, it will be much more helpful to jointly train the
generator and the decoder, utilizing strategies such
as semi-supervised learning[58, 59]. Finally, besides
the three tasks experimented in this work, conditional
graph generator can be used in many other scenar-
ios. To summarize, the graph generative architecture
proposed in this work gives promising result in vari-
ous drug design tasks, and it is worthwhile to explore
other potential applications using this method.
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